Your session is about to expire
← Back to Search
Not Applicable
Prevention Program Adaptation for HIV/AIDS and Substance Abuse in Black Adolescent Girls
N/A
Waitlist Available
Led By Ijeoma Opara, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Identify as a Black/African American female
Be between the ages of 13-18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 30 days, 60 days
Awards & highlights
Study Summary
This trial will use focus groups to understand people's opinions and experiences. Focus groups allow the researcher to hear from many people at once and see how they interact with each other.
Who is the study for?
This trial is for Black/African American girls aged 13-18 living in Paterson, New Jersey. They must speak English as their first language and have both parent consent and youth assent if under 18. It's not open to those who are pregnant, over 18 or under 13, don't identify as Black/African American only, or lack parental consent.Check my eligibility
What is being tested?
The study is testing a theater-based program adapted from SISTA/SIHLE designed for HIV/AIDS and substance abuse prevention among the participants. The effectiveness will be evaluated using focus groups to gather detailed feedback on the interaction between participants.See study design
What are the potential side effects?
Since this intervention involves theater activities and discussions rather than medical treatments, traditional physical side effects are not expected. However, emotional discomfort due to sensitive topics discussed may occur.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a Black/African American woman.
Select...
I am between 13 and 18 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 30 days, 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 30 days, 60 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in 30-day drug use
Change in HIV knowledge
Change in ethnic identity
+3 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Theater/Pilot TestingExperimental Treatment1 Intervention
Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for HIV/AIDS involve antiretroviral therapy (ART), which includes several classes of drugs: nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA; protease inhibitors (PIs) block the protease enzyme, preventing viral replication; integrase strand transfer inhibitors (INSTIs) inhibit the integrase enzyme, preventing the integration of viral DNA into the host genome; and entry inhibitors prevent the virus from entering host cells. These mechanisms are vital as they collectively reduce the viral load, enhance immune function, and prevent the progression to AIDS, thereby significantly improving the quality of life and longevity of HIV/AIDS patients.
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project.Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project.Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,863 Previous Clinical Trials
2,742,571 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,798 Previous Clinical Trials
2,660,908 Total Patients Enrolled
Ijeoma Opara, PhDPrincipal InvestigatorYale University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a Black/African American woman.I am between 13 and 18 years old.I am either younger than 13 or older than 18.I agree to be a part of this study.I am between 13 and 18 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Theater/Pilot Testing
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger